www.ijarp.com ISSN 2456-9992 Page: 01-11

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 08

PREVALENCE AND ANTIFUNGAL SUSCEPTIBILITY PATTERNS OF CANDIDA SPECIES ISOLATED FROM CLINICAL SPECIMENS: A COMPREHENSIVE REVIEW

Akshay*[1], Dr. Rajender Kumar[2], Gurpreet Singh[3], Ayash Ashraf[3]

[1]Department of Medical Laboratory Technology, Guru Kashi University.

[2]Dean, Faculty of Allied and Healthcare, Guru Kashi University.

[3]Assistant Professor, Department of Allied & Healthcare Sciences, Guru Kashi University.

Article Received: 27 June 2026, Article Revised: 17 July 2026, Published on: 04 August 2026

***Corresponding Author: Akshay**

Department of Medical Laboratory Technology, Guru Kashi University.

Doi: https://doi-doi.org/101555/ijarp.6511

ABSTRACT

Candidiasis is one of the most common opportunistic fungal infections affecting both immunocompromised and immunocompetent individuals. The disease is caused by yeasts belonging to the genus Candida, with Candida albicans historically being the predominant pathogen. However, over the past two decades, there has been a remarkable increase in infections caused by non-albicans Candida (NAC) species, many of which exhibit reduced susceptibility or intrinsic resistance to commonly prescribed antifungal agents. The emergence of antifungal resistance has become a significant challenge in clinical practice, leading to prolonged hospitalization, increased healthcare costs, therapeutic failures, and higher mortality rates. This review summarizes the current epidemiology of candidiasis, distribution of Candida species, major virulence factors, laboratory diagnostic approaches, antifungal susceptibility patterns, mechanisms of drug resistance, and strategies for effective infection control. Particular emphasis is placed on the increasing prevalence of non-albicans Candida species and the importance of routine species-level identification and antifungal susceptibility testing for guiding appropriate therapy. Recent evidence demonstrates that Amphotericin B and Voriconazole continue to show excellent activity against most Candida isolates, whereas increasing resistance to Fluconazole among Candida glabrata and Candida krusei remains a growing concern. Continuous surveillance, implementation of antifungal stewardship programs, and adoption of advanced molecular diagnostic techniques are essential for improving patient outcomes and preventing the further emergence of antifungal

resistance.

KEYWORDS: Candida albicans, Non-albicans Candida, Candidiasis, Antifungal susceptibility, Fluconazole resistance, Amphotericin B, Clinical microbiology.

1. INTRODUCTION

Fungal infections have become an increasingly important cause of morbidity and mortality worldwide, particularly among hospitalized patients and individuals with compromised immune function. Among the various fungal pathogens, species belonging to the genus Candida are responsible for the majority of opportunistic fungal infections encountered in clinical practice. Candida species normally exist as commensal organisms colonizing the oral cavity, gastrointestinal tract, respiratory tract, genitourinary tract, and skin. Under normal physiological conditions, these microorganisms coexist harmlessly with the host. However, disruption of host immunity, prolonged antibiotic therapy, diabetes mellitus, malignancy, immunosuppressive treatment, prolonged hospitalization, invasive medical procedures, or indwelling medical devices may transform these commensals into invasive pathogens capable of causing superficial as well as life-threatening systemic infections.

Candidiasis encompasses a broad spectrum of clinical manifestations ranging from localized mucocutaneous infections such as oral thrush, vulvovaginal candidiasis, and cutaneous candidiasis to invasive candidemia and disseminated candidiasis involving multiple organs. Invasive Candida infections remain among the leading causes of healthcare-associated bloodstream infections worldwide and are associated with prolonged hospitalization, increased healthcare expenditure, and mortality rates approaching 40% in critically ill patients. Consequently, rapid diagnosis and effective antifungal therapy are essential for improving clinical outcomes.

Historically, Candida albicans accounted for the majority of clinical isolates; however, recent epidemiological studies have demonstrated a progressive increase in infections caused by non-albicans Candida species, including Candida tropicalis, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida auris. These emerging pathogens are clinically significant because many possess intrinsic or acquired resistance to azole antifungal agents, particularly Fluconazole, thereby complicating therapeutic management. The widespread use of broad-spectrum antibiotics, prolonged antifungal exposure, invasive medical procedures, and expanding populations of immunocompromised patients have contributed significantly to this epidemiological shift.

Accurate identification of Candida species and determination of antifungal susceptibility patterns have therefore become increasingly important components of routine microbiological diagnosis. Conventional culture methods remain widely used; however, advances in chromogenic media, automated identification systems, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), polymerase chain reaction (PCR), and DNA sequencing have substantially improved the speed and accuracy of fungal diagnosis. In addition, standardized antifungal susceptibility testing according to Clinical and Laboratory Standards Institute (CLSI) guidelines facilitates evidence-based therapeutic decision-making and supports antifungal stewardship initiatives.

This review critically evaluates current evidence regarding the epidemiology, virulence mechanisms, laboratory diagnosis, antifungal susceptibility patterns, and resistance mechanisms of Candida species. The review further highlights recent trends in antifungal resistance and discusses strategies for improving diagnosis, treatment, and prevention of candidiasis in healthcare settings.

2. Epidemiology of Candidiasis

Candidiasis remains one of the most frequently encountered opportunistic fungal infections worldwide. The incidence of both superficial and invasive candidiasis has increased considerably over recent decades because of advances in intensive care medicine, increased use of immunosuppressive therapies, prolonged survival of critically ill patients, organ transplantation, widespread use of broad-spectrum antimicrobial agents, and the increasing prevalence of chronic diseases such as diabetes mellitus and malignancy.

Hospital-acquired candidiasis represents a major healthcare challenge. Candida species are currently recognized among the leading causes of bloodstream infections in intensive care units, neonatal intensive care units, oncology centers, and transplant facilities. Mortality associated with invasive candidiasis remains high despite improvements in antifungal therapy, emphasizing the importance of early diagnosis and prompt initiation of appropriate treatment.

Geographical variation significantly influences Candida epidemiology. While Candida albicans continues to predominate globally, several regions have reported increasing isolation of non-albicans Candida species. In India, Candida tropicalis has emerged as the most common non-albicans Candida species isolated from clinical specimens, followed by Candida glabrata, Candida parapsilosis, and Candida krusei. This changing epidemiological pattern has important therapeutic implications because many of these species demonstrate

reduced susceptibility to azole antifungal agents.

Clinical specimen distribution also varies according to infection type. Urine, vaginal swabs, blood, sputum, wound swabs, catheter tips, and oral swabs represent common sources of Candida isolation. Findings from the present thesis demonstrated that urine and vaginal swab specimens accounted for the highest proportion of Candida isolates, while female patients exhibited a slightly higher prevalence of infection than male patients. Furthermore, adults aged 21–40 years constituted the most affected age group, reflecting increased exposure to underlying risk factors such as diabetes mellitus, hormonal influences, prolonged medication use, and urinary tract infections.

The epidemiology of candidiasis has therefore evolved considerably over the past two decades, necessitating continuous surveillance to monitor emerging species, changing susceptibility profiles, and regional variations in antifungal resistance. Such epidemiological information remains indispensable for guiding empirical therapy and developing effective infection prevention strategies.

3. Candida Species and Their Clinical Significance

The genus Candida comprises more than 200 yeast species, although only a limited number are responsible for human disease. Among these, Candida albicans has historically been recognized as the most common etiological agent of candidiasis because of its remarkable virulence, adaptability, and ability to colonize multiple anatomical sites. Nevertheless, recent epidemiological studies have demonstrated a progressive increase in infections caused by non-albicans Candida (NAC) species, including Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida krusei, and the emerging multidrug-resistant pathogen Candida auris. This shift has significant clinical implications because many NAC species exhibit reduced susceptibility or intrinsic resistance to commonly used azole antifungal agents.

The findings of the present study demonstrated that Candida albicans accounted for 50% of all isolates, confirming that it remains the predominant pathogen. However, non-albicans Candida species collectively constituted the remaining 50% of isolates, indicating a substantial epidemiological shift. Among the NAC species, Candida tropicalis was the most frequently isolated, followed by Candida glabrata, Candida krusei, and Candida parapsilosis. These findings are consistent with previous reports from India, where C. tropicalis has emerged as the leading non-albicans pathogen in both superficial and invasive candidiasis.

Each Candida species possesses unique microbiological and clinical characteristics. Candida

albicans is highly virulent because of its ability to form germ tubes, hyphae, pseudohyphae, and biofilms that facilitate tissue invasion and immune evasion. In contrast, Candida tropicalis is frequently associated with bloodstream infections and infections among immunocompromised patients, particularly those with hematological malignancies. Candida glabrata demonstrates increasing resistance to azole antifungal agents and is commonly isolated from elderly patients, diabetic individuals, and patients receiving prolonged antifungal therapy. Candida krusei is intrinsically resistant to Fluconazole, making accurate species identification essential before initiating antifungal treatment. Candida parapsilosis is frequently associated with catheter-related bloodstream infections because of its remarkable ability to colonize medical devices and form biofilms.

The increasing prevalence of NAC species has significantly influenced antifungal treatment guidelines. Since susceptibility patterns vary considerably among different Candida species, routine species-level identification has become an indispensable component of clinical microbiology laboratories. Accurate identification enables clinicians to select the most effective antifungal therapy, minimizes unnecessary drug exposure, and reduces the development of antifungal resistance.

4. Virulence Factors of Candida Species

The pathogenicity of Candida species is determined by multiple virulence factors that enable colonization, tissue invasion, immune evasion, and persistence within the host. These factors contribute to disease severity and explain the remarkable ability of Candida to cause both superficial and invasive infections.

One of the most important virulence characteristics is **morphological switching**. Candida albicans can transition between yeast, pseudohyphal, and hyphal forms depending on environmental conditions. This morphological flexibility enhances tissue penetration, promotes dissemination, and facilitates escape from host immune responses. Hyphal formation is particularly important because filamentous cells invade epithelial tissues more effectively than yeast forms and produce greater tissue damage.

Biofilm formation represents another major virulence mechanism. Biofilms consist of structured microbial communities embedded within an extracellular polymeric matrix that adheres to biological tissues and medical devices such as urinary catheters, central venous catheters, prosthetic heart valves, and orthopedic implants. Biofilm-associated cells exhibit significantly greater resistance to antifungal agents than planktonic cells because the extracellular matrix restricts drug penetration, while altered metabolic activity further reduces

antifungal susceptibility. Consequently, biofilm-associated infections frequently require removal of contaminated medical devices in addition to antifungal therapy.

The secretion of **hydrolytic enzymes**, including secreted aspartyl proteinases, phospholipases, lipases, and hemolysins, further enhances Candida pathogenicity. These enzymes degrade host tissues, facilitate nutrient acquisition, promote tissue invasion, and impair local immune defenses. Secreted aspartyl proteinases, in particular, play a crucial role in epithelial invasion and dissemination of infection.

Another important virulence attribute is the ability to evade host immune responses. Candida species possess sophisticated mechanisms that inhibit phagocytosis, survive intracellularly within macrophages, modify cell wall composition, and regulate expression of immune-evasive proteins. These adaptations enable persistent colonization and chronic infection, especially among immunocompromised individuals.

Collectively, these virulence factors explain the remarkable success of Candida species as opportunistic pathogens and underscore the importance of early diagnosis and appropriate antifungal therapy.

5. Laboratory Diagnosis of Candidiasis

Accurate laboratory diagnosis is essential for effective management of candidiasis because clinical manifestations often resemble those of bacterial or other fungal infections. Prompt species identification combined with antifungal susceptibility testing enables clinicians to initiate appropriate therapy while minimizing treatment failure and antifungal resistance.

Conventional diagnosis begins with direct microscopic examination using potassium hydroxide (KOH) wet mounts, Gram staining, and microscopy of clinical specimens. Budding yeast cells, pseudohyphae, and true hyphae provide preliminary evidence of Candida infection. Although microscopy offers rapid results, definitive diagnosis requires fungal culture.

Culture remains the gold standard for routine laboratory diagnosis. Clinical specimens are commonly inoculated onto Sabouraud Dextrose Agar (SDA), where characteristic creamy white colonies develop following incubation. CHROMagar Candida has become particularly valuable because it differentiates major Candida species based on colony color and morphology, allowing rapid presumptive identification of mixed infections.

Biochemical identification methods, including carbohydrate assimilation and fermentation tests, continue to be used in many diagnostic laboratories. Automated identification systems such as VITEK 2 and BD Phoenix provide rapid and standardized species identification while

reducing turnaround time. More recently, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) has revolutionized fungal diagnostics by enabling rapid, accurate, and cost-effective identification of clinically important Candida species.

Molecular diagnostic techniques, including polymerase chain reaction (PCR), real-time PCR, DNA sequencing, and next-generation sequencing (NGS), further improve diagnostic accuracy, particularly for uncommon or cryptic species. These techniques also facilitate detection of antifungal resistance genes and support epidemiological surveillance. However, their routine implementation remains limited in many developing countries because of financial and technical constraints.

Antifungal susceptibility testing has become an indispensable component of laboratory diagnosis because resistance patterns vary substantially among Candida species. Standardized broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI), together with automated susceptibility testing systems, enable laboratories to determine minimum inhibitory concentrations (MICs) and guide evidence-based antifungal therapy. Routine susceptibility testing is particularly important for infections caused by non-albicans Candida species because of their increasing resistance to azole antifungal agents.

6. Antifungal Susceptibility Patterns

Antifungal susceptibility testing has become an essential component of the clinical management of candidiasis because different Candida species exhibit considerable variation in their response to antifungal agents. The increasing prevalence of non-albicans Candida (NAC) species has further emphasized the importance of performing routine susceptibility testing before initiating antifungal therapy. Standardized testing according to the Clinical and Laboratory Standards Institute (CLSI) guidelines enables clinicians to select the most appropriate antifungal agent, improve treatment outcomes, and minimize the emergence of drug resistance.

The present study demonstrated that Amphotericin B exhibited the highest antifungal activity, with approximately 95% of isolates being susceptible, confirming its continued effectiveness against both Candida albicans and most non-albicans Candida species. Amphotericin B exerts its antifungal action by binding to ergosterol in the fungal cell membrane, resulting in pore formation, leakage of intracellular contents, and fungal cell death. Despite its excellent antifungal efficacy, the clinical use of conventional Amphotericin B remains limited by nephrotoxicity and infusion-related adverse effects. Lipid-based formulations have

substantially improved its safety profile while maintaining therapeutic efficacy.

Voriconazole also demonstrated excellent in vitro activity, with approximately 88% susceptibility among the clinical isolates. As a second-generation triazole antifungal agent, Voriconazole inhibits ergosterol synthesis by targeting the fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase. Owing to its broad antifungal spectrum and favorable pharmacokinetic properties, Voriconazole has become an important therapeutic option for invasive fungal infections, particularly in patients who cannot tolerate Amphotericin B.

In contrast, Fluconazole demonstrated comparatively lower susceptibility because of increasing resistance among non-albicans Candida species. The study observed that Candida glabrata exhibited reduced susceptibility, whereas Candida krusei demonstrated intrinsic resistance to Fluconazole. These findings are consistent with global surveillance studies reporting increasing azole resistance associated with prolonged antifungal exposure, inappropriate empirical therapy, and selective antimicrobial pressure. Consequently, Fluconazole should be prescribed cautiously, particularly when infections are suspected to involve resistant NAC species.

Other antifungal agents, including Itraconazole, Posaconazole, Echinocandins (Caspofungin, Micafungin, and Anidulafungin), and newer triazoles, continue to demonstrate favorable activity against many Candida isolates. Echinocandins, in particular, are recommended as first-line therapy for invasive candidiasis because they inhibit β-(1,3)-D-glucan synthesis, an essential component of the fungal cell wall, while exhibiting minimal toxicity in humans.

The observed susceptibility profile emphasizes the importance of species-specific antifungal susceptibility testing before initiating treatment. Such evidence-based therapy minimizes treatment failure, prevents unnecessary antifungal exposure, and contributes to effective antifungal stewardship.

7. Mechanisms of Antifungal Resistance

The emergence of antifungal resistance among Candida species represents one of the greatest challenges in modern clinical microbiology. Resistance develops through multiple molecular mechanisms that reduce the effectiveness of commonly used antifungal drugs and complicate patient management.

One of the principal mechanisms involves alterations in the ergosterol biosynthesis pathway. Mutations in the ERG11 gene reduce the binding affinity of azole antifungal agents to lanosterol 14-α-demethylase, thereby decreasing drug efficacy. Additionally, overexpression

of efflux pumps, including ATP-binding cassette (ABC) transporters and major facilitator superfamily (MFS) transporters, actively removes antifungal agents from fungal cells before therapeutic concentrations can be achieved.

Biofilm formation also contributes significantly to antifungal resistance. Cells embedded within biofilms exhibit resistance levels many times greater than free-floating planktonic cells because the extracellular matrix limits drug penetration while dormant fungal cells remain metabolically inactive and less susceptible to antifungal agents. Biofilm-associated infections frequently require removal of infected medical devices in addition to antifungal therapy.

Genetic adaptation further enhances resistance through chromosomal rearrangements, gene amplification, and stress-response pathways that allow fungal cells to survive prolonged antifungal exposure. Increasing reports of multidrug-resistant species such as Candida auris illustrate the urgent need for continuous surveillance and development of novel antifungal therapies.

8. Prevention and Infection Control

Prevention of candidiasis requires a multidisciplinary approach involving infection control, rational antimicrobial use, early laboratory diagnosis, and effective antifungal stewardship. Hospital-acquired candidiasis can be significantly reduced through strict adherence to hand hygiene, environmental cleaning, sterilization of medical equipment, and proper management of invasive devices such as urinary catheters and central venous catheters.

Antimicrobial stewardship programs play a vital role in preventing antifungal resistance by promoting the rational use of antifungal agents. Unnecessary or prolonged administration of broad-spectrum antibiotics and azole antifungals should be avoided because they create selective pressure favoring resistant Candida species. Species identification and antifungal susceptibility testing should guide targeted therapy whenever possible.

High-risk patients, including those admitted to intensive care units, transplant recipients, oncology patients, neonates, diabetic individuals, and immunocompromised patients, require careful monitoring for early signs of invasive candidiasis. Rapid diagnosis, prompt initiation of appropriate antifungal therapy, and removal of infected medical devices significantly improve clinical outcomes.

Healthcare workers should receive regular training regarding infection prevention practices, specimen collection, laboratory diagnosis, and antifungal stewardship principles. Continuous microbiological surveillance remains essential for monitoring regional epidemiological trends

and detecting the emergence of resistant Candida species.

9. CONCLUSION

Candidiasis remains one of the most important opportunistic fungal infections affecting hospitalized and immunocompromised patients worldwide. Although Candida albicans continues to be the predominant species isolated from clinical specimens, the increasing prevalence of non-albicans Candida species has significantly altered the epidemiology and therapeutic management of fungal infections. Many of these emerging pathogens demonstrate intrinsic or acquired resistance to commonly prescribed azole antifungal agents, emphasizing the need for accurate laboratory diagnosis and routine antifungal susceptibility testing.

The findings summarized in this review indicate that Amphotericin B and Voriconazole continue to exhibit excellent activity against most clinical Candida isolates, whereas increasing Fluconazole resistance among Candida glabrata and Candida krusei presents an ongoing clinical challenge. Species-level identification combined with standardized susceptibility testing enables clinicians to select effective antifungal therapy, reduce treatment failure, and improve patient outcomes.

Advances in molecular diagnostics, laboratory automation, antifungal stewardship, and infection control will play a critical role in combating the growing threat of antifungal resistance. Continued epidemiological surveillance, research into novel antifungal agents, and interdisciplinary collaboration among clinicians, microbiologists, infection control teams, and public health authorities are essential to ensuring effective management of candidiasis and limiting the emergence of resistant Candida species.

REFERENCES

1. Achkar, J. M., & Fries, B. C. (2010). Candida infections of the genitourinary tract. Clinical Microbiology Reviews, 23(2), 253–273.
2. Arendrup, M. C. (2010). Epidemiology of invasive candidiasis. Current Opinion in Critical Care, 16(5), 445–452.
3. Arendrup, M. C., & Patterson, T. F. (2017). Multidrug-resistant Candida: Epidemiology and treatment. Journal of Infectious Diseases, 216(3), S445–S451.
4. Badiee, P., & Alborzi, A. (2011). Susceptibility of clinical Candida species isolates to antifungal agents. Archives of Iranian Medicine, 14(2), 123–127.
5. Bassetti, M., Merelli, M., Righi, E., Diaz-Martin, A., Rosello, E. M., Luzzati, R., & Rosin, C. (2013). Epidemiology and outcomes of candidemia. Clinical Microbiology and

Infection, 19(9), E84–E90.

6. Borman, A. M., Johnson, E. M., & Muller, J. (2008). Rapid identification of Candida species. Medical Mycology, 46(6), 567–574.
7. Brown, G. D., Denning, D. W., & Levitz, S. M. (2012). Tackling human fungal infections. Science, 336(6082), 647.
8. Calderone, R. A., & Clancy, C. J. (2012). Candida and candidiasis (2nd ed.). ASM Press.
9. Chakrabarti, A., Chatterjee, S. S., Rao, K. L. N., Zameer, M. M., Shivaprakash, M. R., Singhi, S., & Rudramurthy, S. M. (2009). Recent experience with fungaemia. Indian Journal of Medical Microbiology, 27(2), 129–132.
10. Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., & Kaur, H. (2015). Incidence and characteristics of candidemia in India. Journal of Infection in Developing Countries, 9(11), 1141–1150.
11. Clinical and Laboratory Standards Institute. (2021). Performance standards for antifungal susceptibility testing (32nd ed.). CLSI.
12. Colombo, A. L., Nucci, M., Park, B. J., Nouer, S. A., Arthington-Skaggs, B., da Matta, D. A., & Warnock, D. (2006). Epidemiology of candidemia in Brazil. Clinical Infectious Diseases, 42(2), 273–280.